½ÉÀå´ë»çÁõÈıºÇÐȸ 2022 Ãß°è½ÉÆ÷Áö¾ö : 2022-09-03±³À°ÀÏÀÚ : 2022-09-03
±³À°Àå¼Ò : ½ºÀ§½º ±×·£µå È£ÅÚ (Çöó¹Ö°í·ë)
±³À°ÁÖÁ¦ :
½ÉÀå´ë»çÁõÈıºÇÐȸ 2022 Ãß°è½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ½ÉÀå´ë»çÁõÈıºÇÐȸ
´ã´çÀÚ : ±è¼±¿Á
¿¬¶ôó : 02-2273-8556
À̸ÞÀÏ :
apcms@kscms.org ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 55ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í ±³¼ö ¹× °³¿øÀÇ: 4¸¸¿øÀü°øÀÇ, ÀüÀÓÀÇ, ±âŸ: 2¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-03 Flamingo room 09:00~09:20 Obesity and metabolic syndrome treatment with gut microbiome Ȳ¼º¼ø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09-03 Flamingo room 09:20~09:40 Gut microbiome and inflammation : focus on clinical application ±èºÀ¼ö(ÇѸ²´ë »ý¸í°úÇаú)
±³À°½Ã°£ 09-03 Flamingo room 09:40~10:00 Gut microbiome and kidney Á¶»ó°æ(°í·ÁÀÇ´ë)
Åä·Ð 09-03 Flamingo room 10:00~10:20 Discussion Á¶»óÈ£(ÇѸ²ÀÇ´ë)
ÈÞ½Ä 09-03 Flamingo room 10:20~10:50 Coffee Break & Photo Time ()
±³À°½Ã°£ 09-03 Flamingo room 10:50~11:10 Strategy to create value with biomedical data and AI at commercial level ÃÖÈ«À±(Portrai, Inc)
±³À°½Ã°£ 09-03 Flamingo room 11:10~11:30 Current status of big data application in industry ÀÌÇнÂ(Medical AI)
±³À°½Ã°£ 09-03 Flamingo room 11:30~11:50 The future of AI in diagnosis and treatment of heart and metabolic disease Àå¹Î¿Á(VUNO)
Åä·Ð 09-03 Flamingo room 11:50~12:10 Discussion À̹ÎÈ£(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09-03 Flamingo room 12:10~12:25 Cutting edge care of Pitavastatin with Ezetimibe combination therapy ¼¿ø¿ì(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09-03 Flamingo room 12:25~12:40 Optimal BP control strategy for DM patients Á¶µ¿Çõ(¿¬¼¼¿øÁÖÀÇ´ë)
½Ä»ç 09-03 Flamingo room 12:40~13:30 Lunch ()
±³À°½Ã°£ 09-03 Flamingo room 13:30~13:48 AI and cardiovascular medicine À̽Âö(Æ÷Ç×°ø´ë ±â°è°øÇаú)
±³À°½Ã°£ 09-03 Flamingo room 13:48~14:06 Metaverse in heart and metabolic disease treatment À̾ð(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 09-03 Flamingo room 14:06~14:24 Apprehensions about Excessive Belief in Medical Big DATA : Points of Concern Excluding Merits ±èÇ强(°¡Å縯ÀÇ´ë)
Åä·Ð 09-03 Flamingo room 14:24~14:45 Discussion ¹Ú¼º¹Ì(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09-03 Flamingo room 14:45~15:03 Emerging new drug for dyslipidemia: ASO and siRNA , AGPTL3 peptide targeting mAb À§Áø(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 09-03 Flamingo room 15:03~15:21 GIP and GLP-1 agonist combination ±è¿øÁø(Â÷ÀÇ°ú´ëÇÐ)
±³À°½Ã°£ 09-03 Flamingo room 15:21~15:39 New drug for patients with resistant hypertension Á¶À翵(Àü³²ÀÇ´ë)
Åä·Ð 09-03 Flamingo room 15:39~16:00 Discussion È«Áö¿¬(ÇѸ²ÀÇ´ë)
ÈÞ½Ä 09-03 Flamingo room 16:00~16:15 Coffee Break ()
±³À°½Ã°£ 09-03 Flamingo room 16:15~16:33 Vasospastic angina and atherosclerosis ±èÇöÁø(ÇѾçÀÇ´ë)
±³À°½Ã°£ 09-03 Flamingo room 16:33~16:51 TG rich lipoprotein and atherosclerotic CVD ÇãÁöÇý(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09-03 Flamingo room 16:51~17:09 Atherosclerotic disease after recovery COVID 19 infection À念¿ì(°¡ÃµÀÇ´ë)
Åä·Ð 09-03 Flamingo room 17:09~17:30 Discussion ¹Ú¼¼Àº(¼º±Õ°üÀÇ´ë)